Itolizumab [Bmab 600]

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Erythematosus

Conditions

Lupus Erythematosus, Lupus Nephritis

Trial Timeline

Oct 1, 2019 โ†’ Jan 18, 2024

About Itolizumab [Bmab 600]

Itolizumab [Bmab 600] is a phase 1 stage product being developed by Biocon for Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT04128579. Target conditions include Lupus Erythematosus, Lupus Nephritis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04128579Phase 1Completed

Competing Products

20 competing products in Lupus Erythematosus

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
tacrolimusAstellas PharmaPhase 3
77
TacrolimusAstellas PharmaPre-clinical
23
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
77
tacrolimusAstellas PharmaApproved
85
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
77
E6742EisaiPhase 1/2
41
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 2
52
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 1
33
LY3471851 + PlaceboEli LillyPhase 2
52